Biogen Statistics
Total Valuation
Biogen has a market cap or net worth of $23.01 billion. The enterprise value is $27.96 billion.
| Market Cap | 23.01B |
| Enterprise Value | 27.96B |
Important Dates
The last earnings date was Wednesday, October 30, 2024, before market open.
| Earnings Date | Oct 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biogen has 145.72 million shares outstanding. The number of shares has increased by 0.34% in one year.
| Current Share Class | 145.72M |
| Shares Outstanding | 145.72M |
| Shares Change (YoY) | +0.34% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 0.24% |
| Owned by Institutions (%) | 90.44% |
| Float | 145.13M |
Valuation Ratios
The trailing PE ratio is 14.27 and the forward PE ratio is 10.05. Biogen's PEG ratio is 1.76.
| PE Ratio | 14.27 |
| Forward PE | 10.05 |
| PS Ratio | 2.39 |
| Forward PS | 2.38 |
| PB Ratio | 1.41 |
| P/TBV Ratio | 340.37 |
| P/FCF Ratio | 11.81 |
| P/OCF Ratio | 10.82 |
| PEG Ratio | 1.76 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.69, with an EV/FCF ratio of 14.36.
| EV / Earnings | 17.31 |
| EV / Sales | 2.91 |
| EV / EBITDA | 9.69 |
| EV / EBIT | 12.40 |
| EV / FCF | 14.36 |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.41.
| Current Ratio | 1.26 |
| Quick Ratio | 0.68 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | 2.17 |
| Debt / FCF | 3.42 |
| Interest Coverage | 8.62 |
Financial Efficiency
Return on equity (ROE) is 10.47% and return on invested capital (ROIC) is 6.24%.
| Return on Equity (ROE) | 10.47% |
| Return on Assets (ROA) | 4.99% |
| Return on Capital (ROIC) | 6.24% |
| Revenue Per Employee | $1.27M |
| Profits Per Employee | $213,369 |
| Employee Count | 7,570 |
| Asset Turnover | 0.34 |
| Inventory Turnover | 0.86 |
Taxes
In the past 12 months, Biogen has paid $291.70 million in taxes.
| Income Tax | 291.70M |
| Effective Tax Rate | 15.30% |
Stock Price Statistics
The stock price has decreased by -31.22% in the last 52 weeks. The beta is -0.06, so Biogen's price volatility has been lower than the market average.
| Beta (5Y) | -0.06 |
| 52-Week Price Change | -31.22% |
| 50-Day Moving Average | 181.84 |
| 200-Day Moving Average | 207.81 |
| Relative Strength Index (RSI) | 24.44 |
| Average Volume (20 Days) | 1,771,609 |
Short Selling Information
The latest short interest is 3.12 million, so 2.14% of the outstanding shares have been sold short.
| Short Interest | 3.12M |
| Short Previous Month | 3.07M |
| Short % of Shares Out | 2.14% |
| Short % of Float | 2.15% |
| Short Ratio (days to cover) | 2.36 |
Income Statement
In the last 12 months, Biogen had revenue of $9.61 billion and earned $1.62 billion in profits. Earnings per share was $11.06.
| Revenue | 9.61B |
| Gross Profit | 7.26B |
| Operating Income | 2.26B |
| Pretax Income | 1.31B |
| Net Income | 1.62B |
| EBITDA | 2.89B |
| EBIT | 2.26B |
| Earnings Per Share (EPS) | $11.06 |
Balance Sheet
The company has $1.70 billion in cash and $6.65 billion in debt, giving a net cash position of -$4.95 billion or -$33.98 per share.
| Cash & Cash Equivalents | 1.70B |
| Total Debt | 6.65B |
| Net Cash | -4.95B |
| Net Cash Per Share | -$33.98 |
| Equity (Book Value) | 16.36B |
| Book Value Per Share | 112.28 |
| Working Capital | 1.41B |
Cash Flow
In the last 12 months, operating cash flow was $2.13 billion and capital expenditures -$179.60 million, giving a free cash flow of $1.95 billion.
| Operating Cash Flow | 2.13B |
| Capital Expenditures | -179.60M |
| Free Cash Flow | 1.95B |
| FCF Per Share | $13.36 |
Margins
Gross margin is 75.59%, with operating and profit margins of 23.48% and 16.81%.
| Gross Margin | 75.59% |
| Operating Margin | 23.48% |
| Pretax Margin | 19.84% |
| Profit Margin | 16.81% |
| EBITDA Margin | 30.03% |
| EBIT Margin | 23.48% |
| FCF Margin | 16.24% |
Dividends & Yields
Biogen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.34% |
| Shareholder Yield | -0.34% |
| Earnings Yield | 7.02% |
| FCF Yield | 8.46% |
Analyst Forecast
The average price target for Biogen is $260.48, which is 64.97% higher than the current price. The consensus rating is "Buy".
| Price Target | $260.48 |
| Price Target Difference | 64.97% |
| Analyst Consensus | Buy |
| Analyst Count | 25 |
| Revenue Growth Forecast (5Y) | 2.14% |
| EPS Growth Forecast (5Y) | 23.90% |
Stock Splits
The last stock split was on January 18, 2001. It was a forward split with a ratio of 3:1.
| Last Split Date | Jan 18, 2001 |
| Split Type | Forward |
| Split Ratio | 3:1 |
Scores
Biogen has an Altman Z-Score of 3.25 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.25 |
| Piotroski F-Score | 6 |